A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification
Tóm tắt
Từ khóa
Tài liệu tham khảo
Bennett JM, Catovsky D, Daniel MT . Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189–199.
Bartl R, Frisch B, Baumgart R . Morphologic classification of the myelodysplastic syndromes (MDS): combined utilization of bone marrow aspirates and trephine biopsies. Leuk Res 1992; 16: 15–33.
Garand R, Gardais J, Bizet M, Bremond JL, Accard F, Callat MP et al. Heterogeneity of acquired idiopathic sideroblastic anaemia (AISA). Leuk Res 1992; 16: 463–468.
Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088.
Verburgh E, Achten R, Maes B, Hagemeijer A, Boogaerts M, De Wolf-Peeters C et al. Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes. J Clin Oncol 2003; 21: 273–282.
Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835–3849.
Vardiman JW, Harris NL, Brunning RD . The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292–2302.
Germing U, Gattermann N, Aivado M, Hildebrandt B, Aul C . Two types of acquired idiopathic sideroblastic anaemia (AISA): a time-tested distinction. Br J Haematol 2000; 108: 724–728.
Rosati S, Mick R, Xu F, Stonys E, Le Beau MM, Larson R et al. Refractory cytopenia with multilineage dysplasia: further characterization of an ‘unclassifiable’ myelodysplastic syndrome. Leukemia 1996; 10: 20–26.
Malcovati L, Della Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E et al. Prognostic Factors and life expectancy in Myelodysplastic Syndromes classified according to the WHO criteria: A basis for clinical decision making. J Clin Oncol 2005; 23: 7594–7603.
Matsuda A, Germing U, Jinnai I, Misumi M, Kuendgen A, Knipp S et al. Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes. Blood 2005; 106: 2633–2640.
Matsuda A, Jinnai I, Yagasaki F, Kusomoto S, Murohashi I, Bessho M et al. Refractory anemia with severe dysplasia: clinical significance of morphological features in refractory anemia. Leukemia 1998; 12: 482–485.
Tassin F, Dewe W, Schaaf N, Herens C, Ravoet C, Albert A et al. A four-parameter index of marrow dysplasia has predictive value for survival in myelodysplastic syndromes. Leuk Lymphoma 2000; 36: 485–496.
Beutler E, Waalen J . The definition of anemia: What is the lower limit of normal of the blood hemoglobin concentration? Blood 2006; 107: 1747–1750.
Maes B, Meeus P, Michaux L, Bijnens L, Boogaerts M, Hagemeijer A et al. Application of the International Prognostic Scoring System for myelodysplastic syndromes. Ann Oncol 1999; 10: 825–829.
Hast R, Nilsson I, Widell S, Ost A . Diagnostic significance of dysplastic features of peripheral blood polymorphs in myelodysplastic syndromes. Leuk Res 1989; 13: 173–178.
Greenberg P, Anderson J, de Witte T, Estey E, Fenaux P, Gupta P et al. Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study Group. J Clin Oncol 2000; 18: 3447–3452.
Nosslinger T, Reisner R, Koller E, Grüner H, Tüchler H, Nowotny H et al. Myelodysplastic syndromes, from French–American–British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution. Blood 2001; 98: 2935–2941.
Lee JH, Lee JH, Shin YR, Lee JS, Kim WK, Chi HS et al. Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome. Leukemia 2003; 17: 305–313.
Howe RB, Porwit-MacDonald A, Wanat R, Tehranchi R, Hellstrom-Lindberg E . The WHO classification of MDS does make a difference. Blood 2004; 103: 3265–3270.
Germing U, Gattermann N, Strupp C, Aivado M, Aul C . Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 2000; 24: 983–992.
Sanz GF, Sanz MA, Vallespi T, del Canizo MC . Two types of acquired idiopathic sideroblastic anaemia. Br J Haematol 1990; 75: 633–634.
Sanz GF, Sanz MA, Vallespi T, del Canizo MC . Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989; 74: 395–408.
Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D . Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 1985; 59: 425–433.
Morel P, Hebbar M, Lai JL, Duhamel A, Preudhomme C, Wattel E et al. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia 1993; 7: 1315–1323.
Bennett JM, Brunning RD, Vardiman JW . Myelodysplastic syndromes: from French–American–British to World Health Organization: a commentary. Blood 2002; 99: 3074–3075.
Steensma DP, Tefferi A . The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk Res 2003; 27: 95–120.
Tamura S, Takemoto Y, Wada H, Itoh T, Mori A, Saheki K et al. Significance of trilineage myelodysplasia in de novo acute myeloid leukaemia during remission rather than at diagnosis. Br J Haematol 1998; 101: 743–748.